Verrica Pharmaceuticals (NASDAQ:VRCA) Price Target Cut to $18.00 by Analysts at HC Wainwright

Verrica Pharmaceuticals (NASDAQ:VRCA) had its price objective lowered by HC Wainwright from $24.00 to $18.00 in a report published on Tuesday morning, BenzingaRatingsTable reports. HC Wainwright currently has a buy rating on the stock.

VRCA has been the topic of several other research reports. BidaskClub raised shares of Verrica Pharmaceuticals from a sell rating to a hold rating in a research report on Tuesday, June 23rd. Zacks Investment Research cut shares of Verrica Pharmaceuticals from a hold rating to a sell rating in a report on Thursday, June 25th. Northland Securities began coverage on shares of Verrica Pharmaceuticals in a report on Wednesday, June 24th. They issued an outperform rating and a $21.00 target price on the stock. ValuEngine raised shares of Verrica Pharmaceuticals from a hold rating to a buy rating in a report on Tuesday, March 17th. Finally, Needham & Company LLC cut their target price on shares of Verrica Pharmaceuticals from $20.00 to $17.00 and set a buy rating on the stock in a report on Tuesday. One analyst has rated the stock with a sell rating, one has assigned a hold rating and four have assigned a buy rating to the company. The stock has a consensus rating of Buy and an average target price of $16.75.

Shares of VRCA stock opened at $14.07 on Tuesday. The company has a debt-to-equity ratio of 0.61, a quick ratio of 27.45 and a current ratio of 27.45. Verrica Pharmaceuticals has a one year low of $6.79 and a one year high of $18.67. The company’s 50-day simple moving average is $12.05 and its 200-day simple moving average is $12.74. The stock has a market capitalization of $366.31 million, a price-to-earnings ratio of -11.53 and a beta of 2.39.

Verrica Pharmaceuticals (NASDAQ:VRCA) last issued its quarterly earnings results on Thursday, May 7th. The company reported ($0.39) EPS for the quarter, missing the consensus estimate of ($0.38) by ($0.01). As a group, research analysts forecast that Verrica Pharmaceuticals will post -2.32 EPS for the current year.

Large investors have recently made changes to their positions in the business. BlackRock Inc. increased its stake in shares of Verrica Pharmaceuticals by 0.3% during the first quarter. BlackRock Inc. now owns 729,149 shares of the company’s stock valued at $7,970,000 after acquiring an additional 1,884 shares during the period. FMR LLC increased its stake in shares of Verrica Pharmaceuticals by 1.6% during the fourth quarter. FMR LLC now owns 635,680 shares of the company’s stock valued at $10,101,000 after acquiring an additional 10,050 shares during the period. Kornitzer Capital Management Inc. KS increased its stake in shares of Verrica Pharmaceuticals by 5.8% during the first quarter. Kornitzer Capital Management Inc. KS now owns 470,274 shares of the company’s stock valued at $5,140,000 after acquiring an additional 25,743 shares during the period. State Street Corp increased its stake in shares of Verrica Pharmaceuticals by 4.6% during the first quarter. State Street Corp now owns 234,801 shares of the company’s stock valued at $2,566,000 after acquiring an additional 10,277 shares during the period. Finally, Geode Capital Management LLC increased its stake in shares of Verrica Pharmaceuticals by 10.3% during the first quarter. Geode Capital Management LLC now owns 180,065 shares of the company’s stock valued at $1,968,000 after acquiring an additional 16,830 shares during the period. Institutional investors own 34.45% of the company’s stock.

Verrica Pharmaceuticals Company Profile

Verrica Pharmaceuticals Inc, a clinical stage medical dermatology company, develops and commercializes dermatological treatments in the United States. The company's lead product candidate include VP-102 that is in phase III clinical trial for the treatment of molluscum contagiosum; in phase II clinical trial for the treatment of common warts; and completed phase I clinical trial for the treatment of Genital warts.

Featured Article: What does a hold rating mean?

Receive News & Ratings for Verrica Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Verrica Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.